These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Response assessment using Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186 [TBL] [Abstract][Full Text] [Related]
6. Baseline Imaging Derived Predictive Factors of Response Following [ van der Sar ECA; Kühr AJS; Ebbers SC; Henderson AM; de Keizer B; Lam MGEH; Braat AJAT Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884878 [TBL] [Abstract][Full Text] [Related]
7. Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis. Rahbar K; Schmidt M; Heinzel A; Eppard E; Bode A; Yordanova A; Claesener M; Ahmadzadehfar H J Nucl Med; 2016 Sep; 57(9):1334-8. PubMed ID: 27056618 [TBL] [Abstract][Full Text] [Related]
8. Role of baseline Telli TA; Ozguven S; Alan O; Filizoglu N; Ozturk MA; Sariyar N; Isik S; Arikan R; Demircan NC; Basoglu T; Cetin IA; Ones T; Ercelep O; Dane F; Yumuk PF Ann Nucl Med; 2022 Nov; 36(11):964-975. PubMed ID: 35997890 [TBL] [Abstract][Full Text] [Related]
9. Prediction of early biochemical response after 177Lu-PSMA radioligand therapy with 68Ga-PSMA PET, a different perspective with quantitative parameters. Aksu A; Vural Topuz Ö; Yilmaz B; Karahan Şen NP; Acar E; Çapa Kaya G Nucl Med Commun; 2022 Apr; 43(4):468-474. PubMed ID: 35045552 [TBL] [Abstract][Full Text] [Related]
10. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010 [No Abstract] [Full Text] [Related]
11. Heinzel A; Boghos D; Mottaghy FM; Gaertner F; Essler M; von Mallek D; Ahmadzadehfar H Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1054-1062. PubMed ID: 30697649 [TBL] [Abstract][Full Text] [Related]
12. Role of textural heterogeneity parameters in patient selection for 177Lu-PSMA therapy via response prediction. Khurshid Z; Ahmadzadehfar H; Gaertner FC; Papp L; Zsóter N; Essler M; Bundschuh RA Oncotarget; 2018 Sep; 9(70):33312-33321. PubMed ID: 30279962 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of Roll W; Schindler P; Masthoff M; Seifert R; Schlack K; Bögemann M; Stegger L; Weckesser M; Rahbar K Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359750 [No Abstract] [Full Text] [Related]
17. Molecular imaging and biochemical response assessment after a single cycle of [ Rosar F; Hau F; Bartholomä M; Maus S; Stemler T; Linxweiler J; Ezziddin S; Khreish F Theranostics; 2021; 11(9):4050-4060. PubMed ID: 33754047 [No Abstract] [Full Text] [Related]
18. Efficacy and safety of Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197 [No Abstract] [Full Text] [Related]
19. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of [68Ga]Ga-PSMA PET/CT for therapy response assessment of [177Lu]Lu-PSMA radioligand therapy in metastasized castration refractory prostate cancer and correlation with survival. Kurth J; Kretzschmar J; Aladwan H; Heuschkel M; Gummesson A; Bergner C; Kundt G; Hakenberg OW; Krause BJ; Schwarzenböck SM Nucl Med Commun; 2021 Nov; 42(11):1217-1226. PubMed ID: 34424870 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]